Yanzhao WANG None;
Folahan Ibukun None;
Elias Traboulsi Travere Therapeutics, Code C (Consultant/Contractor), Sparing Vision, Code S (non-remunerative);
David Birch Nacuity Pharmaceuticals, Editas, AGTC, PYC Therapeutics, ONL Therapeutics, Bluerock Therapeutics, Aldyra, Novartis, 4D Molecular Therapeutics, Inc., Foundation Fighting Blindness, , Code C (Consultant/Contractor), Biogen, AGTC, 4D Molecular Therapeutics Inc, PYC Therapeutics, Ocugen , Code F (Financial Support);
Janet Sunness Lineage(OpRegen trial), Re-Vision Therapeutics , Code S (non-remunerative);
Rupert Strauss None;
Isabelle Audo Novartis, Janssen, Code C (Consultant/Contractor);
Michel Michaelides MeiraGTx, Stargazer, Belite Bio, Mogrify, Code C (Consultant/Contractor), MeiraGTx, Code I (Personal Financial Interest), Stargazer, Belite Bio, MeiraGTx-Janssen, Code S (non-remunerative);
SriniVas Sadda Apellis, Amgen, Abbvie/Allergan, Alexion, Samsung Bioepis, Biogen, Boerhinger Ingelheim, IvericBio, Novartis, Roche, Bayer, Regeneron, Pfizer, Astellas, Nanoscope, Jannsen, Centervue, Optos, Heidelberg NotalVision, Eyepoint, Character, OTx, Code C (Consultant/Contractor), Novartis, Roche, Optos, Heidelberg , Code R (Recipient), ARVO, Macula Scoiety, Code S (non-remunerative);
Hendrik Scholl Alnylam Pharmaceuticals Inc.; Gerson Lehrman Group Inc.; Guidepoint Global, LLC; and Tenpoint Therapeutics., Code C (Consultant/Contractor), Swiss National Science Foundation, the Wellcome Trust, the Foundation Fighting Blindness Clinical Research Institute, Code F (Financial Support), Ascidian Therapeutics, Inc.; Boehringer Ingelheim Pharma GmbH & Co; Droia NV; Eluminex Biosciences; Gyroscope Therapeutics Ltd.; Janssen Research & Development, LLC (Johnson & Johnson); Okuvision GmbH; ReVision Therapeutics Inc.; and Saliogen Therapeutics Inc,Belite Bio, F. Hoffmann-La Roche Ltd, ViGeneron, Steering Committee of Novo Nordisk , Code S (non-remunerative);
Eberhart Zrenner None;
Michael Ip Alimera, Allergan, Amgen, Apellis, Clearside Biomedical, Genentech, IVERIC Bio, Novartis, Regeneron, Regenxbio, Code C (Consultant/Contractor), Apellis, Biogen, Genentech, IVERIC Bio, Lineage Cell Therapeutics, ONL Therapeutics, Regenxbio, 4DMT, Code F (Financial Support);
Artur Cideciyan None;
Paul Bernstein None;
Xiangrong Kong None